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In 1962, the science historian Thomas Samuel Kuhn
described a paradigm as not just current scientific theory, but
rather the entire world view that encompassed this knowl-
edge (1). Scientific progress is made when there are anom-
alies that cannot be explained in one paradigm, leading to a
paradigm shift. In some cases, old paradigms are revisited,
synergistic with rapid advances in scientific knowledge and
innovation. In these cases, there is augmentation of estab-
lished therapeutic interventions to new avenues; recent
examples include percutaneous coronary intervention, endo-
vascular intervention of aortic aneurysms, transcatheter
valvular therapy, and endovascular intervention for erectile
dysfunction (ED). Fundamental to endovascular therapy,
we must first consider the body of literature that establishes
the importance for penile arterial insufficiency (PAI) in ED.
Leriche (2) first described this association in 1932 in a
patient with bilateral aorto-iliac disease and ED. However,
this association remained unexplored until 1978, when 30
males with ED underwent translumbar aortography fol-
lowed by puncture of the dorsal artery of the penis,
demonstrating severe arterial stenosis or occlusion to the
corporal bodies (3). Since then, 10 studies have assessed
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penile arterial blood flow in 629 patients with ED (4–14).
Collectively, these studies showed that the incidence of PAI
ranges between 37% and 79%, with an average incidence of
76%. These observations established the association be-
tween PAI and ED and framed arterial reconstruction or
intervention as a possible therapeutic option. Initially, mi-
crosurgical reconstruction of penial arterial circulation was
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arterial conduits with a variable extent of penile venous
reconstruction (15). Altogether, 31 studies were performed;
however, only 4 reports for a total of 50 patients have been
considered of adequate quality by the American Urological
Association (15). Even these 4 studies were limited by
inadequate study design, lack of long-term follow-up, a
wide range of complications, and heterogenous surgical
approaches. Most importantly, none of these studies were
performed for atherosclerotic PAI, but rather for focal
stenosis resulting from blunt trauma. However, because of
these findings, the American Urological Association con-
siders vascular reconstructive approaches for ED experi-
mental and has advised against it.
Given these surgical limitations, transluminal angioplasty
(without stenting) was attempted in the 1980s and 1990s,
treating a total of 65 patients with a mean success rate of
55% (Table 1) (16–21). The overwhelming majority of the
endovascular interventions (95%, n 62) were to larger iliac
arteries, with only 3 internal pudendal artery (IPA) inter-
ventions. In addition, none of the studies had any nonin-
vasive methods of documenting PAI before or after inter-
vention. Similarly, venous insufficiency, an important
mechanism for ED, was not assessed. Given the limitations
of study design, patient selection, and endovascular tech-
niques used in these studies, the role of endovascular
intervention in ED has remained unclear and is rarely
considered, unless for treatment of proximal iliac disease in
the setting of peripheral artery disease.
Given recent endovascular advances, Rogers et al. (22), in
this issue of the Journal, conducted a seminal first-in-man
prospective, multicenter, single-arm safety and feasibility
trial of the zotarolimus-eluting stent implantation in focal
atherosclerotic lesions of the IPA among men with ED with
suboptimal responses to phosphodiesterase-5 inhibitors. A
total of 383 men were screened using stringent clinical,
angiographic, and duplex ultrasonographic criteria. Of the
89 patients who underwent pelvic angiography, 67% (n 
60) had severe IPA stenosis, but of those, only 33.7% (n 
30) had suitable anatomic features amenable to intervention.
The location of atherosclerosis in the IPA was distal
(53.3%), followed by proximal or ostial segments (24.4%),
and the mean lesion length was 17.6  99 mm. Forty-five
lesions were treated with stents, and technical success was
achieved in all patients with no post procedural death or
perineal gangrene at 30 days through follow-up (primary
safety endpoint). The angiographic percent stenosis pre-
procedure was 63.3%, and this reduced to 23.3% post-
procedure, but increased again to 41.4% at 6 months. In
addition, there was a nonsignificant increase in peak systolic
velocity from 14.4  10.7 cm/s to 22.5  23.7 cm/s at 6
months in conjunction with binary restenosis of 34.4% (n
11). Despite the moderate improvement in peak velocity
and significant restenosis rate, in the intention-to-treat
analysis, the primary feasibility endpoint (improvement
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more in more than 50% of subjects) at 3 and 6 months
was achieved by 59.3% of patients (95% confidence
interval: 38.8 to 77.6).
This study presents the first major step in the application
of endovascular intervention and provides several insights
for the potential treatment of ED. Of the 383 subjects
screened, only 89 (23%) qualified for angiography, and of
those, only 30 (7.8%) qualified for the intervention, high-
lighting the need for appropriate patient selection. Even
more importantly, approximately 30% of subjects that met
the peak systolic velocity and other inclusion criteria had
minimal to normal angiographic appearance, emphasizing
the need for more robust, noninvasive screening tools such
as computed tomography or magnetic resonance imaging.
Furthermore, PAI is a diffuse process, similar to that seen in
patients with critical limb ischemia, and discrete lesions are
seen in only one third of patients. Therefore, stents alone
may not be the best answer for all patients. The procedure,
however, seems to be feasible and safe, but there is a high
degree of anatomic variability requiring significant operator
experience.
The main limitation of this study is the lack of a control
arm. In addition, the post-procedure peak systolic velocity,
an indication that blood flow improved, did not reach
statistical significance. Furthermore, despite a 34.4% binary
restenosis rate, efficacy remained at 59.4% at 6 months;
hence, the long-term durability of endovascular therapy is
unknown. Collectively, these limitations and findings raise
concern about the placebo effect. This is supported by a 22%
improvement in erectile function in patients receiving pla-
cebo in studies evaluating oral phosphodiesterase-5 inhibi-
tors (23). Moreover, the primary feasibility endpoint was
selected based on prior studies of oral agents to improve
ED; however, given the risk and cost, it is not clear whether
this endpoint is appropriate for invasive procedures.
Despite the limitations outlined above, the current study sets
the stage for advancing this important field further. Erectile
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First Author, Year (Ref.#) No.
Angiographic
Stenosis
Follow-up
(months)
Success
Rate (%)
Castaneda-Zuniga et al.
1982 (16)
2 ILA 18 100
Van Unnik and Marsman,
1984 (17)
1 ELA N/A 100
Goldwasser et al., 1985 (18) 1 ILA N/A 100
Dewar et al., 1985 (19) 30 70% aorto-iliac,
47% ILA
N/A 33
Angelini et al., 1985 (20) 5 ILA 2 to 18 80
*Urigo et al., 1994 (21) 23 ILA, IPA N/A 65, 100
*In this study, 65% of patients with internal iliac artery stenosis had improvement in erectile
function, whereas all patients with pudendal artery disease had success.
ELA external iliac artery; ILA internal iliac artery; IPA internal pudendal artery; N/A not
vailable; PTA  percutaneous transluminal balloon angioplasty.dysfunction is a vascular disease, and a team of experts(urology, cardiology, and primary care) at each center should
work collectively to identify, evaluate, and treat these patients.
The presence of atherosclerotic lesions in the pelvis does not
necessarily result in ED. Unfortunately, the Incidence of Male
Pudendal Artery Stenosis in Suboptimal Erections (IM-
PASSE) study, which was designed to better understand this
association, recently was terminated.
At present, endovascular therapy for ED remains inves-
tigational; however, given the prevalence of ED and its
psychosocial impact, an appropriately powered randomized
clinical trial to evaluate this approach clearly is needed.
Before doing so, this field is in desperate need of a
reproducible and easily performed noninvasive diagnostic
tool that can identify PAI and exclude venous leak accu-
rately for proper patient selection and to avoid unnecessary
procedures. Only then can this paradigm be revisited.
Reprint requests and correspondence: Dr. Mehdi H. Shisheh-
bor, Endovascular Services, Heart & Vascular Institute, Cleveland
Clinic, 9500 Euclid Avenue, J3-05, Cleveland, Ohio 44195.
E-mail: shishem@ccf.org.
REFERENCES
1. Kuhn TS. The structure of scientific revolutions. Chicago, IL: Uni-
versity of Chicago Press, 1962.
2. Leriche R. The syndrome of thrombotic obliteration of the aortic
bifurcation. Ann Surg 1948;127:193–206.
3. Michal V, Pospichal J. Phalloarteriography in the diagnosis of erectile
impotence. World J Surg 1978;2:239–48.
4. Herman A, Adar R, Rubinstein Z. Vascular lesions associated with
impotence in diabetic and nondiabetic arterial occlusive disease.
Diabetes 1978;27:975–81.
5. Michal V, Kramar R, Pospichal J, Hejhal L. Direct arterial anasto-
mosis on corpora cavernosal penis in the therapy of erectile impotence.
J Sex Med 2008;5:1062–5.
6. Struyven J, Gregoir W, Giannakopoulos X, Wauters E. Selective
pudendal arteriography. Eur Urol 1979;5:233–42.
7. Huguet JF, Clerissi J, Juhan C. Radiologic anatomy of pudendal artery.
Eur J Radiol 1981;1:278–84.
8. Buvat J, Lemaire A, Buvat-Herbaut M, Guieu JD, Bailleul JP, Fossati P.
Comparative investigations in 26 impotent and 26 nonimpotent diabetic
patients. J Urol 1985;133:34–8.
9. Bruhlmann W, Pouliadis G, Zollikofer C, Hauri D. Arteriography of
the penis in secondary impotence. Urol Radiol 1982;4:243–9.
10. Gray RR, Keresteci AG, St Louis EL, et al. Investigation of impo-
tence by internal pudendal angiography: experience with 73 cases.
Radiology 1982;144:773–80.
11. Nessi R, De Flaviis L, Bellinzoni G, Freri F, Salvini A. Digital
angiography of erectile failure. Br J Urol 1987;59:584–9.
12. Valji K, Bookstein JJ. Transluminal angioplasty in the treatment of
arteriogenic impotence. Cardiovasc Intervent Radiol 1988;11:245–52.
13. Rosen MP, Greenfield AJ, Walker TG, et al. Arteriogenic impotence:
findings in 195 impotent men examined with selective internal
pudendal angiography. Young Investigator’s Award. Radiology 1990;
174:1043–8.
14. Rogers JH, Karimi H, Kao J, et al. Internal pudendal artery stenoses
and erectile dysfunction: correlation with angiographic coronary artery
disease. Catheter Cardiovasc Interv 2010;76:882–7.
15. HellstromWJ, Montague DK, Moncada I, et al. Implants, mechanical
devices, and vascular surgery for erectile dysfunction. J Sex Med
2010;7:501–23.
16. Castaneda-Zuniga WR, Gomes A, Weens C, Ketchum D, Amplatz K.
Transluminal angioplasty in the management of mesenteric angina. Rofo
1982;137:330–2.
22
2630 Shishehbor and Philip JACC Vol. 60, No. 25, 2012
Endovascular Treatment of Erectile Dysfunction December 25 2012:2628–3017. Van Unnik JG, Marsman JW. Impotence due to the external iliac steal
syndrome treated by percutaneous transluminal angioplasty. J Urol
1984;131:544–5.
18. Goldwasser B, Carson CC 3rd, Braun SD, McCann RL. Impotence
due to the pelvic steal syndrome: treatment by iliac transluminal
angioplasty. J Urol 1985;133:860–1.
19. Dewar ML, Blundell PE, Lidstone D, Herba MJ, Chiu RC. Effects of
abdominal aneurysmectomy, aortoiliac bypass grafting and angioplasty on
male sexual potency: a prospective study. Can J Surg 1985;28:154–6, 159.
20. Angelini G, Pezzini F, Mucci P. [Arteriosclerosis and impotence].
Minerva Psichiatr 1985;26:353–17.21. Urigo F, Pischedda A, Maiore M, et al. [Role of arteriography and
percutaneous transluminal angioplasty in the diagnosis and treat- pment of arterial vasculogenic impotence]. Radiol Med 1994;
88:86–92.
2. Rogers JH, Goldstein I, Kandzari DE, et al. Zotarolimus-eluting
peripheral stents for the treatment of erectile dysfunction in subjects
with suboptimal response to phosphodiesterase-5 inhibitors. J Am
Coll Cardiol 2012;60:2618–27.
3. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD,
Wicker PA. Oral sildenafil in the treatment of erectile dysfunction.
Sildenafil Study Group. N Engl J Med 1998;338:1397–404.
Key Words: endovascular treament y erectile dysfunction y internal
udendal artery y penile arterial insufficiency.
